Pevion Biotech Ag


BERN, Switzerland, October 11, 2011 - Pevion Biotech AG today announced latest results from the ongoing clinical study of its therapeutic Candida vaccine PEV7, showing high levels of specific antibodies and a 100% mucosal immune response rate.

BERN, Switzerland, September 1, 2011 - Pevion Biotech AG today announced that the company has granted to CSL Limited a right of first refusal for the commercialization of its therapeutic Candida vaccine in Australia and New Zealand.

BERNE, Switzerland, April 21, 2011 - Pevion Biotech AG today announced that Jean-Paul Prieels has joined its Board of Directors.

ITTIGEN, Switzerland and BERN, Switzerland, February 10, 2011 - Pevion Biotech Ltd.

ITTIGEN and BERN, Switzerland, November 11, 2010 - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).
Older News
S M T W T F S
25 26 27 28 29 30 1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
Copyright© 2011 The Gaea Times